¾ç´ë½Ä

¾ç´ë½Ä
¼¼ºÎÀü°ø
À¯¹æ¾Ï, Æó¾Ï, ºÎÀΰúÁ¾¾ç, ºñ´¢±â¾Ï, ¸²ÇÁ°èÁ¾¾ç
Áúȯ±º
À¯¹æ¾Ï, Æó¾Ï, ÀڱðæºÎ¾Ï, Àڱ󻸷¾Ï, Àü¸³¼±¾Ï, ¹æ±¤¾Ï, ¾Ç¼º¸²ÇÁÁ¾
Áõ»ó±º
À¯¹æÁ¾¹°, ÆóÁ¾¾ç, ÁúÃâÇ÷, ¹è´¢°ï¶õ, Ç÷´¢, ¸²ÇÁÁ¾¹°

¾ç´ë½Ä ±³¼öÀÇ Áø·á½Ã°£Ç¥ Áø·á¿¹¾à

Áø·á°ú/¼¾ÅÍ ¿ù È­ ¼ö ¸ñ ±Ý Åä Àü¹®Áø·á°ú¸ñ
¹æ»ç¼±Á¾¾çÇаú - - - - - - À¯¹æ¾Ï, ºÎÀξÏ, ÀÓÆÄÁ¾ (¿¬±¸³â(2023.03~2023.08))
¾Ïº´¿ø(3F) - - - - - - À¯¹æ¾Ï, ºÎÀξÏ, ÀÓÆÄÁ¾

¾ç´ë½Ä ±³¼öÀÇ »ó¼¼Á¤º¸

ÇзÂ

more
  • 1989 .02  ~   :  °í·Á´ëÇб³ ÀÇ°ú´ëÇÐ Á¹¾÷
  • 2003 .02  ~   :  °í·Á´ëÇб³ ´ëÇпø ÀÇÇаú Á¹¾÷ (ÀÇÇйڻç)

°æ·Â

more
  • 1995 .03  ~  1999 .02  :  °í·Á´ëÇб³ ¾È¾Ïº´¿ø ¹æ»ç¼±Á¾¾çÇаú Àü°øÀÇ
  • 1999 .03  ~  2002 .02  :  °í·Á´ëÇб³ ¾È¾Ïº´¿ø ¹æ»ç¼±Á¾¾çÇаú ÀüÀÓÀÇ
  • 2002 .03  ~  2005 .02  :  °í·Á´ëÇб³ ¾È¾Ïº´¿ø ¹æ»ç¼±Á¾¾çÇаú ÀÓ»óÁ¶±³¼ö
  • 2005 .03  ~  2008 .02  :  °í·Á´ëÇб³ ¾È¾Ïº´¿ø ¹æ»ç¼±Á¾¾çÇаú ÀÓ»óºÎ±³¼ö
  • 2008 .03  ~  2010 .02  :  °í·Á´ëÇб³ ±¸·Îº´¿ø ¹æ»ç¼±Á¾¾çÇаú ÀÓ»óºÎ±³¼ö
  • 2010 .03  ~   :  °í·Á´ëÇб³ ±¸·Îº´¿ø ¹æ»ç¼±Á¾¾çÇаú ÀÓ»ó±³¼ö

³í¹®

more
  • [SCI] (Association of a TGF-¥â1 gene-509 C/T polymorphism with breast cancer risk: a meta-anlaysis)
  • [±¹³»³í¹®] °í¾Ç¼ºµµ ½Å°æ¾Æ±³Á¾ÀÇ ¼ö¼ú ÈÄ ¹æ»ç¼± Ä¡·á ¼ºÀû°ú ¿¹ÈÄÀÎÀÚ ºÐ¼®
  • [SCI] (Association of a vascular endothelial growth factor gene 936 C/T polymorphism with breast cancer risk: a meta-analysis)
  • [±¹³»³í¹®] (Analysis of the Dosimetric Characteristics of Normoxic Polymer Gel by Magnetic Resonance Images Analysis of the Dosimetric Characteristics of Normoxic Polymer Gel by Magnetic Resonance Images Analysis of the Dosimetric Characteristics of Normoxic Polymer Gel by Magnetic Resonance Images)
  • [SCI] (Association of a progesterone receptor gene +331 G/A polymorphism with breast cancer risk: a meta-analysis)
  • [SCI] (Phase II study of vinorelbine monotherapy in anthracycline and taxane pretreated metastatic breast cancer)
  • [SCI] (Bevacizumab for salvage treatment of metastatic breast cancer: a systemic review and meta-analysis of randomized controlled trials.)

ÃÖÁ¾¼öÁ¤ÀÏ : 2023.05.08